Figure 5

Effect of inhibitors of IKK2 and MAP kinases upon IL-1β-induced miR-146a and primary miR-146a expression. HASM cells were pre-treated for 60 min with the indicated concentrations of the inhibitors of IKK-2 (TPCA-1), MEK-1/2 (PD098059), JNK-1/2 (SP600125) and p38 MAP kinase (SB203580). Following exposure to vehicle control or IL-1β (1 ng/ml) for 24 h the expression of miR-146a and primary miR-146a was determined by qRT-PCR. Results are the mean ± SEM of 3 independent experiments where * p < 0.05 versus IL-1β-stimulated cells.